Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 11/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 9/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | MAT2A | P31153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736477 | 0.93 | BCAT1 (0.38) | BCAT1BCAT2GRM4MAT2A | |
| SCHEMBL21615919 | 0.83 | BCAT1 (0.39) | BCAT1BCAT2GRM4MAT2A | |
| SCHEMBL4736723 | 0.83 | BCAT1 (0.39) | BCAT1BCAT2GRM4MAT2A | |
| SCHEMBL23436185 | 0.82 | L3MBTL1 (0.41) | BCAT1BCAT2MEN1KMT2ANPSR1 | |
| SCHEMBL6635645 | 0.82 | BCAT1 (0.35) | BCAT1BCAT2GRM4MAT2A | |
| SCHEMBL130065 | 0.82 | BCAT1 (0.39) | BCAT1BCAT2MAT2A | |
| SCHEMBL2594502 | 0.81 | BCAT1 (0.41) | BCAT1BCAT2GRM4MAT2A | |
| SCHEMBL12430766 | 0.81 | BCAT1 (0.37) | BCAT1BCAT2MAT2A | |
| SCHEMBL10086757 | 0.80 | BCAT1 (0.37) | BCAT1BCAT2GRM4MAT2A | |
| SCHEMBL13064462 | 0.79 | BCAT1 (0.35) | BCAT1BCAT2MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163446-A1 | URACIL COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163446-A1 | URACIL COMPOUNDS AND USE THEREOF | UNG, UMPS, TYMS | BCAT1 187/4885BCAT2 247/4885GRM4 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.